SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community debates the impact of a recent purchase of TSLA stock by Elon Musk, with some seeing it as a positive signal and others suspecting market manipulation. Concerns about global sales figures and increasing competition in the EV sector are also being discussed alongside speculation about future ventures like AI and robotics. The stock's volatile price action is fueling both bullish and bearish sentiment, with traders closely watching key technical levels.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as the community rallies around its decentralized nature and Bitcoin foundation, touting it as more than just a memecoin but a movement. Conversations highlight its fair distribution and organic community, with some mentioning a Coinbase listing review. The broader discussion centers on $DOG.X being the premier memecoin on the Bitcoin network.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Asset Entities Inc.

Asset Entities Inc. ($ASST) is trending due to volatility following its merger, with community members debating the impact of a recently announced offering and buyback program. Discussions also revolve around high short interest, margin requirements, and borrow fees, with some traders hoping for a potential short squeeze, while others express concern about dilution and trading restrictions on some platforms.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around recent dips, viewing them as buying opportunities before upcoming utility releases. The community is actively discussing strategies to push the coin to new ATHs, fueled by bullish sentiment and a strong belief in the project's long-term potential. Community members are anticipating a potential airdrop at the 5 million MC milestone.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as community members discuss its potential role in powering AI data centers and strategic uranium reserves. Bullish sentiment is fueled by the company's innovative approach to nuclear energy, while others express concerns about its current valuation and lack of revenue. Traders are actively debating entry and exit points as the stock experiences volatility.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics ($GLUE) is trending due to a licensing agreement with Novartis potentially worth up to $5.7 billion, sparking excitement about the company's future and potential for significant growth. The community is discussing potential short squeezes and target prices, with some speculating about a possible acquisition. Some traders are noting the high short interest and unusual volume, while others discuss possible resistance levels and near-term price movements.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as the community discusses its potential as a major cloud provider following the Northern Data acquisition, with some highlighting Tether's increased ownership and the upcoming Rumble wallet. Community members are also focused on the platform's ties to figures in the Trump administration, anticipating a shift in media spending and spotlighting the all-time high short interest as a possible squeeze opportunity.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is trending as conversations revolve around the potential for government contracts and its strategic positioning in uranium and rare earth elements. Community members are actively discussing the company's dual narrative and debating whether it is currently undervalued. The stock's movement is also influenced by broader trends in the uranium sector and discussions around energy independence.

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is experiencing significant volatility as traders discuss a recent partnership announcement focused on Solana cryptocurrency. Community members are pointing to unusual volume and potential short squeezes, while also debating the merits of the company's new crypto strategy and upcoming catalysts. The stock is garnering attention as a low float runner and potential pump and dump, with some traders citing technical indicators and prior price action.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending amid community discussions around a potential short squeeze, driven by high short interest and option activity. Some traders are pointing to recent partnerships and technical indicators as bullish signals, while others caution about potential dilution and overvaluation, contributing to the stock's volatility. Broader interest in the quantum computing sector and upcoming catalysts, such as DARPA funding, may also be influencing the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR Capricor Therapeutics, Inc. Sued for Securities Law Violations...

Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR

Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR Faruqi & Faruqi Reminds Capricor Investors of the Pending...

Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates

Quanterix (QTRX) delivered earnings and revenue surprises of -14.63% and -12.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Replimune Group Inc. (REPL) were in the retail spotlight on Wednesday after the stock nearly doubled in value.BMO Capital expects the stock to witness a meaningful rally following the exit of Vinay Prasad from the U.S. Food and Drug Administration, according to TheFly. Prasad stepped down as Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.Meanwhile, shares of Capricor Therapeutics (CAPR) and Sarepta Therapeutics (SRPT) clocked moderate gains.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">Replimune</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1244/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_12_32_01_PM_png_ac2aea7c7b.webp" alt="REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits" width="1244" height="130"><figcaption>REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>As per Stocktwits data, retail chatter around Replimune surged over 1500% over the past 24 hours.Prasad was appointed in May to replace Peter Marks, who was removed from CBER after conflicting with Health and Human Services Secretary Robert F. Kennedy Jr. over vaccine policy.BMO Capital analyst Evan Seigerman views the exit of Vinay Prasad as a positive for the biopharma sector. A new director will "likely be more permissive of innovation than what we have seen to date," the analyst told investors in a research note.BMO, however, remains uncertain on whether a new CBER director will reconsider the denial of approval to the company’s lead product candidate, RP1.Earlier this month, Replimune received a letter from the FDA indicating that it is unable to approve the company’s application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency deemed the trials cited by the company as not adequate to substantiate the effectiveness of the drug. The FDA also said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.The company then said it will request a meeting with the FDA as it plans to interact with the agency to find a path for approval. CEO Sushil Patel stated that the company is surprised and disappointed by the decision.Leerink, meanwhile, views the exit of Prasad as a positive for rare disease and genetic medicines, negative for vaccines, and unclear for oncology, as per TheFly. While Prasad restricted the use of COVID-19 vaccines during his tenure, Leerink expects the new chief to be more in alignment with Robert F. Kennedy Jr. and his anti-vaccine stance.Shares of <a href="https://stocktwits.com/symbol/CAPR">Capricor</a> Therapeutics also traded 25% higher on Wednesday. The FDA had earlier refused to approve its lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-names-former-gm-exec-to-lead-commercial-vehicle-segment/choXEl9R5C4">Ford Names Former GM Executive To Lead Commercial Vehicle Segment: Retail’s Skeptical Ahead Of Q2 Earnings Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Stock Nearly Doubled In Value Today: What's Going On?

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job. 

Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector

Equity

FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks

Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.

Capricor Therapeutics (CAPR) on Friday said the U.S. Food and Drug Administration (FDA) has refused to approve its lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.<a href="https://stocktwits.com/symbol/CAPR">CAPR shares</a> were trading 39% lower in the pre-market session.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/319/capricor-therapeutics-provides-regulatory-update-on">told</a> Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness and expressed the need for additional clinical data.Capricor said the health regulator also referenced certain outstanding items in the Chemistry, Manufacturing, and Controls (CMC) section of the application.The company said it plans to engage further with the FDA to determine the next appropriate steps.Capricor CEO Linda Marbán expressed surprise at the FDA’s decision, calling it “unexpected.” &nbsp;“We have followed their guidance throughout the process. Prior to the CRL (complete response letter), the review had advanced without major issues, including a successful pre-licensure inspection and completion of the mid-cycle review,” she said.The CEO added that the company plans to submit data from a late-stage trial of 104 patients to provide additional evidence of effectiveness. Results from the study are expected in the third quarter of 2025.“We believe these data, if positive, along with our existing long-term clinical results showing cardiac stabilization, preservation of skeletal muscle function, and a consistent safety profile, could support efforts to resolve the questions raised by the FDA for the treatment of cardiomyopathy associated with DMD,” she said.Duchenne Muscular Dystrophy is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, which is the leading cause of death in DMD.DMD therapies have been under increased scrutiny since last month after the FDA <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-stock-slumps-after-fda-opens-probe-into-patient-death-analyst-sounds-alarm/chmJnVnRREn">announced</a> it is investigating the death of two pediatric patients with Duchenne Muscular Dystrophy (DMD) following treatment with Sarepta Therapeutics’ (SRPT) FDA-approved gene therapy Elevidys.FDA is investigating the risk of acute liver failure with serious outcomes, including hospitalization and death, following Elevidys, and is evaluating the need for further regulatory action, the agency said.On Stocktwits, retail sentiment around Capricor remained unmoved within ‘bearish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1364/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_11_at_8_36_02_AM_png_93fa8a7f51.webp" alt="CAPR's Sentiment Meter and Message Volume as of 8:35 a.m. ET on July 11, 2025 | Source: Stocktwits" width="1364" height="128"><figcaption>CAPR's Sentiment Meter and Message Volume as of 8:35 a.m. ET on July 11, 2025 | Source: Stocktwits</figcaption></figure> CAPR stock is down by 17% this year but up by over 148% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-opens-recall-query-into-nearly-28000-polestar-2-vehicles/ch8c9BwR5Zd">US Regulator Opens Recall Query Into Nearly 28,000 Polestar 2 Vehicles, But Retail’s Buoyant</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Capricor Stock Plunges Pre-Market After US FDA Declines Approval For Muscular Disorder Therapy

The FDA told Capricor in a letter that it is unable to approve its application for Deramiocel in its current form as it does not meet the requirement for substantial evidence of effectiveness and expressed the need for additional clinical data.

Jasper Therapeutics faced a wave of downgrades Monday after disclosing that a compromised drug product lot disrupted results in multiple cohorts of its Phase 1b/2a BEACON study evaluating briquilimab for chronic spontaneous urticaria (CSU), a skin allergy.BMO Capital cut the stock to 'Market Perform' from 'Outperform' and slashed its price target to $4 from $15, citing uncertainty caused by manufacturing issues that made it “challenging to separate the signal from the noise.”Cantor Fitzgerald also downgraded the shares to 'Neutral' from 'Overweight', saying the update “introduced uncertainty for clinical trial execution and development timelines.”&nbsp;The firm said it would wait for clarity on future Phase 2b regimens and timelines before re-engaging.William Blair issued a similar downgrade to 'Market Perform' from 'Outperform', flagging a lack of clarity around funding and concerns over the inactive drug lot, which also led Jasper to halt briquilimab development in asthma.&nbsp;The company confirmed that the affected batch was used in all patients in its ETESIAN asthma study.BTIG reduced its price target to $20 from $64 but maintained a 'Buy' rating, calling briquilimab “safe and active” with “compelling efficacy,” despite the paused asthma trial and delayed Phase 2b CSU start, now expected mid-2026.H.C. Wainwright dropped its target to $20 from $40 and retained a 'Buy' rating, citing the “surprising update” on the affected cohorts.&nbsp;The research firm shifted U.S. launch estimates for CSU and chronic inducible urticaria to 2030 and 2031, respectively, and now models a $5 million capital raise.Jasper said the affected cohorts — 240 mg Q8W and 240 mg loading dose plus 180 mg Q8W — showed little to no clinical response, with 10 of 13 patients dosed from the compromised batch.&nbsp;The company plans to replace the products for those patients and enroll 10–12 more across both cohorts. New data is expected in the fourth quarter.Across other cohorts, briquilimab produced deep and durable disease control.&nbsp;In the 240 mg and 360 mg single-dose groups, 8 of 9 participants achieved a complete response, with strong reductions in UAS7 and tryptase levels.&nbsp;Results from the open-label extension study also showed promising efficacy.Jasper is halting asthma and SCID development and may restructure to cut costs and extend its runway.However, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/JSPR">Jasper Therapeutics</a> on Stocktwits was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said Jasper looked oversold and predicted a move above $5, calling the reaction to the update an overreaction to 90% good news.<stembedurl>https://stocktwits.com/trt102967/message/620133879</stembedurl>Another user compared the situation to&nbsp;<a href="https://stocktwits.com/symbol/CAPR/news">Capricor Therapeutics</a> , which dropped last month after reports that&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-slumps-on-report-of-key-fda-exec-removal/chlxVk2RRPt">two key FDA officials</a> overseeing the company’s cell therapy application were placed on administrative leave.<stembedurl>https://stocktwits.com/jlove0303/message/620128019</stembedurl>Jasper Therapeutics’ stock has declined 85.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jasper Therapeutics (JSPR) is investigating a compromised drug batch in its briquilimab skin allergy trial/ Photo credit: Getty Images

Jasper Therapeutics Gets Hit With Downgrades Over Faulty Batch Of Skin Allergy Drug; Retail Sees ‘Overreaction’

The company flagged that 10 of 13 patients in two dosing cohorts received a compromised batch of briquilimab, leading to muted results.

Capricor (CAPR) Moves 20.4% Higher: Will This Strength Last?

Capricor (CAPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Capricor Therapeutics (CAPR) said on Tuesday that the U.S. Food and Drug Administration is not eyeing an advisory committee meeting regarding approval for its Deramiocel for the treatment of Duchenne Muscular Dystrophy (DMD) associated cardiomyopathy.Capricor shares were trading 19% higher at the time of writing.The FDA indicated that an advisory committee meeting is not required at this time, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/318/capricor-therapeutics-provides-regulatory-update-on">said</a>, while adding that its application for Deramiocel approval remains under priority review.The company said in May that the FDA is considering an advisory committee meeting, dragging down investor optimism for a possible approval.The agency is expected to decide on the approval of the drug by Aug. 31. &nbsp;Company CEO Linda Marbán said that all regulatory milestones to date have proceeded as expected, and no major issues were noted at the mid-cycle review of the application.An in-person late-cycle meeting is now scheduled for mid-July.Deramiocel is Capricor’s lead cell therapy candidate for Duchenne Muscular Dystrophy, a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.On Stocktwits, retail sentiment around Capricor stayed unchanged within the ‘extremely bullish’ territory over the past 24 hours while message volume remained ‘extremely high.’<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_12_58_45_PM_png_3f23c3492d.webp" alt="CAPR's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 24, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>CAPR's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the drug getting approved early following the company’s update.<stembedurl>https://stocktwits.com/Drichman7/message/618833665</stembedurl>However, Roth Capital analyst Boobalan Pachaiyappan told investors in a research note that the FDA's intention not to require a meeting "at this time" for Deramiocel “may not necessarily be positive news.”The analyst believes a promissory advisory committee meeting would be positive, as a potential positive panel vote would put pressure on the new FDA leadership to approve deramiocel in its current form.The firm reiterates a ‘Buy’ rating and $31 price target on Capricor shares.H.C. Wainright, however, opined that even in bear case scenarios with the FDA, late-stage trial data readouts are "waiting in the wings" to further strengthen Deramiocel's overall clinical and regulatory package. The analyst believes Deramiocel's first-in-class therapeutic profile, in tandem with strong manufacturing support, will get the therapy over the finish line on expected timelines, as per TheFly.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by about 34% this year but up by about 91% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-presses-congress-to-pass-tax-bill-and-get-the-deal-done-this-week-after-iran-israel-ceasefire/chm4iPpRR3L">Trump Presses Congress To Pass Tax Bill And ‘Get The Deal Done’ This Week After Iran-Israel Ceasefire</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Therapeutics Says FDA May Not Hold Advisory Committee Meeting For DMD Therapy Approval: Stock Soars But Analyst Issues Warning

The FDA has indicated that an advisory committee meeting is not required at this time, the company said, while adding that its application for Deramiocel approval remains under priority review.

Shares of Capricor Therapeutics (CAPR) tumbled 16% on Friday morning following reports that Nicole Verdun, director of the office that reviews cell and gene therapies at the Food and Drug Administration, and her deputy have been placed on administrative leave.Stat News on Wednesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.statnews.com/2025/06/18/top-gene-therapy-regulator-forced-out-at-fda/">reported</a>, citing a recording of a meeting, that Verdun and her deputy Rachael Anatol were escorted out of the agency, sending CAPR shares down on Friday morning. Verdun was the FDA's key overseer of Capricor's application for approval of its Deramiocel drug.Capricor on Friday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/317/capricor-therapeutics-announces-positive-4-year-data-from">announced</a> positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.Deramiocel is Capricor’s lead cell therapy candidate for Duchenne Muscular Dystrophy, a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.Last month, Capricor announced after a mid-cycle review meeting that the FDA is on track to decide on its application by the end of August, the deadline. No significant issues or major deficiencies were noted at the time of the mid-cycle review.A late-cycle meeting is now planned for mid-July.Capricor on Friday said that after four years of continuous treatment, Deramiocel-treated patients showed preservation of cardiac function, including Left Ventricular Ejection Fraction, which is a measurement of how well the left ventricle, the heart's main pumping chamber, is working.Treatment also continued to slow the progression of skeletal muscle disease, the company said, while adding that the findings suggest that extended treatment with Deramiocel may help attenuate the progression of DMD over time.CEO Linda Marbán said that the company is moving toward potential approval of the therapy, with several key regulatory steps now completed.“Our continued dialogue with the FDA remains on track with no evidence of any delays,” she said.On Stocktwits, retail sentiment around Capricor jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_20_at_10_35_01_AM_png_6034c09f71.webp" alt="CAPR's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 20, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>CAPR's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that, although things don't look good, the new 4-year data from the study could ‘change things’ for Capricor.<stembedurl>https://stocktwits.com/MrMarB/message/618459744</stembedurl><a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by 33% this year but has more than doubled its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/uniswap-uni-fair-gas/chlxZJTRRPA">Uniswap Makes Fees Someone Else’s Problem</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data

Capricor on Friday announced positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CAPR News

CAPR Capricor Therapeutics Inc